Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION-Breast05
NCT06103864Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Nov 2023
- Primary completion
- Jul 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 24
01
Overview
A Phase 3 trial of datopotamab deruxtecan in triple-negative breast cancer (TNBC), sponsored by AstraZeneca. Started Nov 2023; status: recruiting.
02
Drugs
datopotamab deruxtecan
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06103864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06103864.